The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.
According to the company, it has shipped more than 1,700 of the IVD analyzer platforms since launching sales globally in 2017.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
Nursing home lab testing, traditionally a low margin and labor intensive business, has been particularly impacted by PAMA-driven reimbursement cuts.
About 200,000 LabCorp patients may have had their credit card or bank information improperly accessed by the breach, which also hit 11.9 million Quest patients.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.
Proceeds from the loan facility will go toward the acquisition of Envigo's nonclinical research services business and other general corporate purposes.
The virology department at UW will offer a number of support services to diagnostics developers, including particular expertise in digital PCR and sequencing technologies.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
A Roche executive said he expects essentially all the firm's US troponin customers will convert to the high-sensitivity assay over the next two to three years.
A decades-long decline in medical technician training programs and large numbers of looming retirements have labs scrambling to fill their vacancies.
The company reported revenues of $222.5 million, down from $254.9 million in Q1 2018, and below the consensus Wall Street estimate of $241.3 million.
According to PathGroup, the deal will broaden its testing menu and adds more than 120 pathologists covering all pathology sub-specialties to the company.
While the impact on participants' bottom lines remains to be seen, some lab company leaders said they expect to see other payors explore similar plans.
Organizations including Quest, J&J, Medecision, and the ACCP have formed the Get the Medications Right (GTMRx) Institute to promote PGx testing.
The company posted Q1 revenues of $2.79 billion, down from $2.85 billion in the same quarter last year, and below Wall Street estimates of $2.83 billion.
The firm's clinical service revenues were up also 51 percent, and it also announced it has signed a contract with insurer Humana.
The company has split bloodstream infection testing into three multiplex panels that can detect a total of 56 pathogen targets and 10 markers of antimicrobial resistance.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.